Beam Therapeutics Inc. Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment
Beam Therapeutics Inc. (BEAM) reported Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment · last filed 2021-11-08
- Beam Therapeutics Inc. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2021-09-30 was $0.00.
- Beam Therapeutics Inc. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2020-09-30 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-10 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |